Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note published on Monday. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 4.3 %

Shares of BCLI opened at $1.57 on Monday. The company has a market cap of $8.95 million, a price-to-earnings ratio of -0.33 and a beta of 0.74. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89. The company has a 50 day moving average of $1.87 and a two-hundred day moving average of $2.26.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.